Description

Overview
Tirzepatide (LY3298176) is a groundbreaking synthetic peptide and dual receptor agonist that simultaneously targets both the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and the Glucagon-like Peptide-1 (GLP-1) receptor. As one of the most extensively studied and clinically evaluated peptide compounds of the past decade, Tirzepatide has generated significant scientific interest for its potent effects on glucose metabolism, energy homeostasis, and body composition regulation. Apex Sequence Labs offers Tirzepatide at the highest purity standards, rigorously tested and manufactured under strict quality control protocols to ensure consistency and reliability for advanced scientific research.

Molecular Profile
Full Name: Tirzepatide (LY3298176)
Type: Dual GIP/GLP-1 Receptor Agonist
Molecular Formula: C???H???N??O??
Molecular Weight: ~4813.5 g/mol
CAS Number: 2023788-19-2
Purity: 99% (HPLC verified)
Form: Lyophilized powder
Half-Life: Approximately 5 days (designed for once-weekly dosing in research models)

Research Areas of Interest
Tirzepatide stands as one of the most clinically advanced and scientifically scrutinised peptide molecules in contemporary metabolic research. Its dual mechanism of action has opened new frontiers across multiple research disciplines:
Glucose Metabolism & Glycaemic Control – Extensively studied for its potent glucose-lowering effects through dual incretin receptor activation, Tirzepatide has demonstrated remarkable efficacy in modulating insulin secretion, suppressing glucagon release, and improving overall glycaemic control in both preclinical and clinical research models. Its glucose-dependent mechanism of action makes it a particularly valuable research tool for studying type 2 diabetes pathophysiology.
Body Composition & Obesity Research – Perhaps the most compelling area of Tirzepatide investigation, clinical research has documented significant reductions in body weight and fat mass across study populations, establishing it as a landmark compound in the field of obesity research. Studies have explored its effects on both subcutaneous and visceral adipose tissue, providing valuable insights into the mechanisms of weight regulation.
Cardiovascular Research – Investigated for its potential cardioprotective properties, including favourable effects on lipid profiles, blood pressure, arterial stiffness, and inflammatory markers associated with cardiovascular disease. Research has also explored its potential role in reducing major adverse cardiovascular events (MACE) in high-risk metabolic disease populations.
Hepatic & Metabolic Research – Studied for its effects on hepatic fat accumulation, liver enzyme normalisation, and improvement of metabolic markers associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), offering researchers a valuable investigational tool in hepatic metabolic disease research.
Insulin Sensitivity & Beta Cell Research – Investigated for its ability to improve peripheral insulin sensitivity, enhance beta cell function, and potentially preserve beta cell mass in models of progressive pancreatic dysfunction, providing unique insights into the pathophysiology of type 2 diabetes progression.
Appetite & Satiety Neurobiology – Researched extensively for its central and peripheral effects on appetite regulation, including modulation of hypothalamic hunger signalling, gastric emptying, and satiety hormone release, contributing to a deeper understanding of the neurobiology of food intake and energy balance.
Renal Research – Emerging research has begun to explore Tirzepatide’s potential nephroprotective effects, including reductions in albuminuria and improvements in renal function markers in metabolic disease models, positioning it as a subject of growing interest in diabetic nephropathy research.
Polycystic Ovary Syndrome (PCOS) Research – Investigated in models of hormonal and metabolic dysregulation associated with PCOS, with studies examining its effects on insulin resistance, androgen levels, and reproductive hormone profiles.

What Sets Tirzepatide Apart?
Tirzepatide’s unique dual agonism distinguishes it from earlier generation GLP-1 single agonists such as Semaglutide and Liraglutide. Key differentiators of scientific interest include:
GIP Receptor Co-activation – The additional GIP receptor agonism introduces a complementary incretin pathway, enabling researchers to study the additive and synergistic metabolic effects of dual incretin engagement versus GLP-1 monotherapy
Superior Glycaemic Efficacy – Clinical research has consistently demonstrated greater HbA1c reductions compared to GLP-1 single agonists, making it a valuable comparator compound in glucose metabolism studies
Enhanced Weight Reduction – Research data has shown greater body weight reductions compared to leading GLP-1 single agonists, making it a critical reference compound in obesity and metabolic research
Novel GIP Biology – Tirzepatide has served as a key research tool in advancing scientific understanding of GIP receptor biology and its previously underappreciated role in metabolic regulation
Once-Weekly Pharmacokinetic Profile – Its extended half-life provides researchers with a practical once-weekly dosing model for longitudinal metabolic studies

Quality Assurance
All Apex Sequence Labs peptides are:
Synthesized using advanced solid-phase peptide synthesis (SPPS)
Third-party tested via HPLC and Mass Spectrometry
Produced in a controlled, sterile, ISO-compliant laboratory environment
Supplied with a Certificate of Analysis (CoA) available upon request
Packaging & Storage
Available in: 2mg | 5mg | 10mg vials
Storage: Store lyophilized peptide at 20°C away from light and moisture
Once reconstituted: Store at 4°C and use within 28 days
Recommended diluent: Bacteriostatic water or sterile water for injection
Shelf life: 24 months when stored correctly in lyophilized form

Why Choose Apex Sequence Labs?
– 99% purity guaranteed
– Independent third-party testing on every batch
– Certificate of Analysis provided
– Produced in ISO-compliant cleanroom facilities
– Fast, discreet shipping
– Dedicated researcher support team

– Research Use Only Disclaimer
Tirzepatide supplied by Apex Sequence Labs is intended strictly for in vitro and in vivo laboratory research purposes only. This product is NOT intended for human or veterinary use, is NOT a drug or dietary supplement. While Tirzepatide (brand name Mounjaro®/Zepbound®) is an FDA-approved pharmaceutical product manufactured by Eli Lilly, the research-grade Tirzepatide supplied by Apex Sequence Labs is an independently synthesised research compound and is not affiliated with, endorsed by, or equivalent to any approved pharmaceutical product. By purchasing this product, the buyer confirms they are a qualified researcher and accepts full responsibility for its lawful and ethical use in accordance with all applicable local, state, and federal regulations.